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There is broad consensus on surgical resection being the backbone of curative therapy of gastric- and
gastroesophageal junction carcinoma. Nevertheless, details on therapeutic approaches in addition to surgery, such
as chemotherapy, radiotherapy or radiochemotherapy are discussed controversially; especially whether external
beam radiotherapy should be applied in addition to chemotherapy and surgery is debated in both entities and
differs widely between regions and centers. Early landmark trials such as the Intergroup-0116 and the MAGIC trial
must be interpreted in the context of potentially insufficient lymph node resection. Despite shortcomings of both
trials, benefits on overall survival by radiochemotherapy and adjuvant chemotherapy were confirmed in populations
of D2-resected gastric cancer patients by Asian trials.
Recent results on junctional carcinoma patients strongly suggest a survival benefit of neoadjuvant
radiochemotherapy in curatively resectable patients. An effect of chemotherapy in the perioperative setting as
given in the MAGIC study has been confirmed by the ACCORD07 trial for junctional carcinomas; however both the
studies by Stahl et al. and the excellent outcome in the CROSS trial as compared to all other therapeutic
approaches indicate a superiority of neoadjuvant radiochemotherapy as compared to perioperative chemotherapy
in junctional carcinoma patients. Surgery alone without neoadjuvant or perioperative therapy is considered
suboptimal in patients with locally advanced disease.
In gastric carcinoma patients, perioperative chemotherapy has not been compared to adjuvant radiochemotherapy
in a randomized setting. Nevertheless, the results of the recently published ARTIST trial and the Chinese data by
Zhu and coworkers, indicate a superiority of adjuvant radiochemotherapy as compared to adjuvant chemotherapy
in terms of disease free survival in Asian patients with advanced gastric carcinoma. The ongoing CRITICS trial is
supposed to provide reliable conclusions about which therapy should be preferred in Western patients with gastric
carcinoma. If radiotherapy is performed, modern approaches such as intensity-modulated radiotherapy and image
guidance should be applied, as these methods reduce dose to organs at risk and provide a more homogenous
coverage of planning target volumes.
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Although mortality in gastric cancer has declined rapidly
during the last century and continues to decrease [1], it
still accounts for 10,340 deaths [2] per year in the US
and 8.1% of all cancer deaths in Europe [3]. Worldwide,
gastric cancer is the fourth and fifth most common can-
cer in males and females [4]. While overall gastric cancer
incidence is decreasing, the incidence of adenocarcin-
oma of the gastric cardia and of the lower esophagus is
increasing in most developed Western populations [5-7].
In Eastern populations, where gastric carcinoma in gen-
eral is more common, adenocarcinomas of the gastroe-
sophageal junction (GEJ) are still rare [8,9]. It is unclear,
if this is caused by an absence of Western risk factors,
such as obesity [10], smoking, and drinking habits [11]
in Eastern patients. Epidemiologic studies in Japan even
suggested that the mentioned (Western) risk factors are
not related to the occurrence of GEJ carcinoma in Asian
patients [8]. The shift of gastric cancer location towards
cardia and GEJ, as well as the histological trend from
squamous cell carcinoma (SCC) to adenocarcinoma in
Western populations creates currently changes in the
basis for therapeutic recommendations.
This review summarizes most recent data of Eastern
and Western trials on gastric and junctional cancer treat-
ment in addition to surgery. We provide in detail a com-
parison of the newer results with early landmark trials and
discuss technical approaches when radiotherapy is per-
formed in addition to chemotherapy (CT) and surgery.
Classification of GEJ carcinoma – gastric, esophageal, or
as an own entity
Whether GEJ adenocarcinomas should be classified as
gastric or esophageal carcinomas or as an own entity is
an issue that has been discussed for years [12-14]. The
classification proposed by Siewert et al. [13] distin-
guished three types of GEJ carcinoma, Type I being con-
sidered as adenocarcinoma of the distal esophagus,
infiltrating the GEJ from above, Type II being the true
carcinoma of the cardia arising immediately at the GEJ,
and Type III, the subcardial gastric carcinoma that infil-
trates the GEJ from below. Although this classification
was based purely on anatomical/topographic parameters,
it was accepted by most surgeons [15,16]. In the 7th
American Joint Committee on Cancer (AJCC) staging
manual [17,18] GEJ cancer is now classified as esopha-
geal cancer even within the first 5 cm of the stomach if
it invades the junction, meaning that in addition to
Siewert I, the former Siewert II and even Siewert III
lesions are now both classified as esophageal carcinoma
[17]. This new classification which is currently not
accepted by all authors [16] makes an appropriate inter-
pretation of results from therapeutic trials difficult, asGEJ carcinomas that were formerly classified as gastric
carcinoma are now staged as esophageal carcinoma.
Taken together, there is an ongoing discussion about
classification of GEJ carcinomas as gastric or esophageal
cancer. They were included in clinical trials on both can-
cers. Therefore detailed knowledge of the respective
population in each trial is necessary when results of
esophageal or gastric cancer trials are applied to GEJ
adenocarcinoma patients.
The dispute on lymph node dissection
With regard to the high incidence of gastric and the in-
creasing incidence of GEJ carcinoma, it comes as a sur-
prise that therapeutic approaches differ widely in terms
of surgical approach especially concerning extended vs.
limited lymph node dissection [19-22], and (neo-)
adjuvant therapy. Basically, according to the classifica-
tion by the Japanese Gastric Cancer Association (JGCA),
most perigastric lymph nodes are defined as group 1,
whereas the distant perigastric nodes, the nodes along
the common hepatic artery, splenic artery, celiac axis
and proper hepatic artery are defined as group 2 [23]. In
the discussion about lymph node resection, most sur-
geons of the Western world favored a limited en bloc re-
section of group 1 nodes with the stomach (D1) because
of increased perioperative mortality associated with the
additional resection of group 2 nodes (D2) [19,21].
In contrast to the trials in the West, in Eastern trials,
extended resection (D2) approaches for gastric carcinoma
were applied with good results since the 1960s [23].
Current data from Western populations are indicating an
emerging consensus that D2 resection with sparing of
pancreas and spleen (also called D1+) is not associated
with increased perioperative mortality [20,22]. Although a
recent update of the Dutch D1D2 trial [20] indicated a sig-
nificantly decreased gastric cancer-related death rate in
the D2 group as compared to D1, it remains to be proven
whether D2/D1+ vs. D1 resection in Western populations
significantly increases overall survival (OS) [24].
When it comes to lymphadenectomy in esophageal
carcinomas of the lower third and in GEJ adenocarcin-
omas, two-field lymphadenectomy with dissection of
lymph nodes in the lower half of the chest and in the
upper abdominal compartment has been widely accepted
as a compromise between the benefits of extended sur-
gery and postoperative morbidity [25].
In gastric- and GEJ carcinoma, therefore, the best sur-
gical approach is still discussed, especially regarding the
extension of lymph node dissection. Although surgical
techniques have been improved greatly during the last
years, there is still a high rate of failure in local control
[26] as well as a high rate of distant metastases, stressing
the importance of systemic and local therapeutic
approaches in addition to surgery.
Table 1 Patient characteristics, side effects and survival in different gastric cancer trials
Clinical Trial INT-0116 MAGIC ACTS-GC CLASSIC ARTIST Zhu 2012
Number of patients 556 503 1059 1035 458 380
Tumor location Stomach: 80% GEJ: 20% Stomach: 74%;
esophagus: 14.5%;
GEJ: 11.5%
100% stomach 97.7% stomach;
2.3% GEJ
100% stomach 80.5% stomach;
19.5% GEJ
Treatment in CT/CRT arm Resection (D2: 10%),
adjuvant FU/FA with
45/1.8Gy*
Perioperative 6 cycles
of FU/epirubicin/cisplatin;
D2 resection in 42.5%†
D2 (94.7%) or
D3 (5.3%) surgery;
adjuvant S-1
D2 surgery;
Adjuvant
capecitabine
and oxaliplatin
D2 resection,
adjuvant XP,
45/1.8Gy/capecitabine;
2 cycles XP§
D2 resection;
1 cycle adjuvant
FU/FA; 45/1.8Gy
IMRT/FU/FA;
followed by 2
cycles FU/FA
Treatment in control arm‡ Resection alone
(D2: 10%)*
D2 resection in
40.4% of cases†
D2 (93.8%) or
D3 (6%) resection
(D1 in 0.2%)
D2 surgery D2 surgery;
adjuvant XP
D2 resection;
adjuvant FU/FA
only
AJCC/UICC stage (or TNM)
in CT/CRT arm
T1-2: 31%; T3-4: 69%;
N0: 16%; N+: 84%‡‡
T1-2: 51.7%; T3-4:
48.3%; N0: 31.1%;
N+: 68.9%‡‡
II: 44.6%; IIIA: 38.2%;
IIIB: 17.0%; IV: 0.2%
IB: <1%; II: 49%;
IIIA: 37%;
IIIB: 14%; IV: 0%
IB: 21.3%; II: 36.5%;
IIIA: 23%; IIIB: 7.8%
IV: 11.3%
IB: 10.8%; II: 19.4%;
III: 55.4%; IV: 14.5%
AJCC/UICC stage (or TNM)
in control‡ arm
T1-2: 31%; T3-4: 68%;
N0: 14%; N+: 85%‡‡
T1-2: 36.8%;
T3-4: 63.2%;
N0: 26.9%;
N+: 73.1%‡‡
II: 44.9%; IIIA: 39.1%;
IIIB: 16.0%; IV: 0%
I: 0%; II: 51%;
IIIA 36%; IIIB 13%;
IV: <1%
IB: 21.9%; II: 37.7%;
IIIA: 21.1%; IIIB: 7.5%;
IV: 11.8%
IB: 9.1%; II: 18.2%;
III: 58.2%; IV: 14.5%
OS in CT/CRT arm# 3-yr: 50% (p=0.005)
5-yr: ~42%
3-yr: ~42%
5-yr: 36.3% (p=0.008)
3-yr: 80.1% (p=0.003)
5-yr: 71.7%
3-yr: 83% (p=0.0493) Unspecified 5-yr: 48.4%
(p=0.122)
3-yr: ~62%
OS in control‡ arm# 3-yr: 41% (p=0.005) 3-yr: ~31%
5-yr: 23.0% (p=0.008)
3-year: 70.1%
(p=0.003)
5-yr: 61.1%
3-yr: 78%
(p=0.0493)
Unspecified 5-yr: 41.8%
(p=0.122)
3-yr: ~53%
DFS in CT/CRT arm# 3-yr: 48% (p<0.001)
5-yr: ~40%
3-yr: ~40% (p<0.001) 3-yr: 72.2%
(p<0.001)
5-yr: 65.4%
3-yr: 74%
(p<0.0001)
3-year: 78.2%
(p=0.0862)§§
3-yr: ~59% 5-yr:
45.2% (p=0.029)
DFS in control‡ arm# 3-yr: 31% (p<0.001) 3-yr: ~24% (p<0.001) 3-yr: 59.6%
(p<0.001)
5-year: 53.1%
3-yr: 59%
(p<0.0001)
3-year: 74.2%
(p=0.0862)§§
3-yr: ~47% 5-yr:
35.8% (p=0.029)
Grade 3–4 hematologic
events in CRT/CT arm
Hematologic events: 54%;
most common: leukopenia;
no further details specified
Leukopenia:
11.5% Neutropenia:
27.8% Lymphopenia:
19.9% Thrombopenia: 3%
Leukopenia: 1.2%
Neutropenia
and Lymphopenia
unspecified
Thrombopenia: 0.2%
Leukopenia:
unspecified
Neutropenia: 22%
Lymphopenia:
unspecified
Thrombopenia: 8%
Leukopenia:
unspecified
Neutropenia:
48.5% Lymphopenia:
unspecified
Thrombopenia: 0.9%
Leukopenia: 7.5%
Neutropenia and
Lymphopenia
unspecified
Thrombopenia: 0%
Grade 3–4 hematologic
events in control‡ arm
Unspecified Unspecified Leukopenia: 0.4%
Thrombopenia: 0.4%
Leukopenia:
unspecified
Neutropenia:
<1% Thrombopenia: 0%
Leukopenia:
unspecified
Neutropenia: 40.7%
Thrombopenia: 0%
Leukopenia: 7.3%
Neutropenia:
unspecified
Thrombopenia: 0%
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Table 1 Patient characteristics, side effects and survival in different gastric cancer trials (Continued)
Most common grade 3–4
non-hematologic events
in CRT/CT arm
Gastrointestinal:
33% Influenza-like:
9% Infection: 6%
Nausea:
12.3% Vomiting:
10.1% Stomatitis: 4.3%
Anorexia: 6%
Nausea: 3.7%
Diarrhea: 3.1%
Nausea: 8%
Vomiting: 7%
Decreased
appetite: 5%
Nausea: 12.3%
Vomiting:
3.1% Hand-foot
syndrome: 3.1%
Nausea: 2.7%
Vomiting: 1.6%
Diarrhea: 1.6%
Most common grade 3–4
non-hematologic events
in control‡ arm
Unspecified Unspecified Anorexia: 2.1%
Vomiting: 1.9%
Nausea: 1.1%
Each single
event <1%
Nausea: 12.4% Vomiting:
3.5% Hand-foot
syndrome: 2.2%
No grade 3–4
non-hematologic
toxicities in CT
group
* D2 resection in 10% of patients, D1 in 36%, and D0 in 54% of patients; curative resection was inclusion criterion; radiotherapy was conventional 2d therapy.
† Patients that did not receive D2 resection were D1-, D0 or non-curatively resected; R0 resection was achieved in 69.3% of patients in CT arm and in 66.4% in surgery only arm.
§ XP: capecitabine and cisplatin; in the CRT group, 2 cycles XP were administered, followed by CRT: 45Gy in 1.8Gy fractions, concomitant capecitabine, followed by another 2 cycles of XP.
§§ In a subgroup analysis of 396 N+ patients, there was a significant prolongation in DFS in the adjuvant CRT arm as compared to the adjuvant CT arm: 3-year DFS 77.5% vs. 72.3%; p=0.0365.
‡ In INT-0116, MAGIC, ACTS-GC, and CLASSIC control arm was surgery only; in ARTIST trial and Zhu 2012 trial, adjuvant CT without radiotherapy was considered as control arm and adjuvant CRT as CT/CRT arm.
‡‡ Patient populations between INT-0116 and MAGIC should be compared in control groups only; the treatment group in MAGIC refers to patients who received CT before surgery and were therefore staged down.
#Survival data marked with “~” are estimates from the published survival curves.
Patient characteristics, outcome and side effects in different gastric cancer trials are summarized. In the MAGIC trial, randomization was performed before surgery; patients in the other trials were randomized after
curative surgery had been performed. The method of randomization after surgery in the INT-0116 trial and the low rate of curative resections in the MAGIC trial distort any direct comparison of results between these
landmark trials. The ARTIST trial and the Chinese trial by Zhu et al. compare CT to CRT in an adjuvant setup of gastric cancer patients. In the ARTIST trial, an improved DFS by CRT as compared to CT was demonstrated
in trend in the whole population; this observation was significant in the subgroup of N+ patients. Zhu et al. reported in a Chinese population a significantly improved DFS (by CRT vs. CT) in all patients, this
inconsistency most probably being due to the more advanced patients in the Chinese trial. A direct comparison in terms of AJCC stage between ARTIST and the trial by Zhu et al. is not possible as in the ARTIST trial,
patients were staged according to the 6th AJCC staging system; Zhu and coworkers reported patient classification according to the 7th AJCC staging system.
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evidence on GEJ- and gastric carcinoma patients
Discussions about therapeutic approaches in addition to
surgery in gastric and GEJ carcinoma patients have
emerged since the first trial in a randomized setting, US
intergroup study (INT)-0116 [27] demonstrated a sig-
nificant improvement in OS and disease free survival
(DFS) in patients with advanced gastric and junctional
(20%) cancer with adjuvant radiochemotherapy (CRT)
vs. surgery alone. This study was heavily criticized due
to the high rate of D0 dissections (see Table 1 for
details); however, benefits on OS of the experimental
arm of the INT-0116 treatment protocol were soon con-
firmed in a non-randomized trial on a population of D2-
resected Eastern patients by Kim et al. [28], and
extended to other CRT protocols by further randomized
trials as detailed below. Recently, an update of the INT-
0116 trial showed that results remained stable in the
long term [29]. The authors additionally provided infor-
mation on the risk of secondary malignancies in the
treatment arm. Although they observed a higher inci-
dence of second tumors in the CRT arm, Smalley et al.
consider this being biased by: 1. improved survival in the
CRT arm, and: 2. completeness of reporting for second
primaries in the treatment arm. Therefore, it seems rea-
sonable to conclude that benefits of CRT outweighed
the risk of second malignancies in this setting [29,30].
In contrast to the INT-0116 study, three randomized
trials on Western patients, randomized to adjuvant CT
with different therapeutic regimens (but without radiation)
vs. surgery alone failed to significantly increase survival in
stomach cancer [31-33]. Despite the disappointing results
on adjuvant CT, Cunningham et al. demonstrated the su-
periority of perioperative CT vs. surgery alone. The
authors enrolled a mixed population of gastric (74%), GEJ
(15%) and esophageal (11%) cancer patients in the Medical
Research Council Adjuvant Gastric Cancer Infusional
Chemotherapy (MAGIC) study [34].
Patients were randomized to surgery alone vs. peri-
operative CT with ECF, a combination of fluorouracil
(FU), cisplatin and epirubicin, administered as described
in Table 1. The MAGIC trial was the first to convin-
cingly demonstrate a survival benefit using CT in West-
ern gastric carcinoma patients. Nevertheless, it has been
criticized for similar reasons as the INT-0116 trial: the
majority of patients received potentially insufficient lym-
phadenectomy (see Table 1). Therefore some authors
argued that CRT or perioperative CT only compensated
for inadequate surgery [35]. In addition, many authors
have criticized the MAGIC trial for the persistence of
methodological biases related to poor staging accuracy
[36], heterogeneity of tumors included, as well as the
lack of quality control in the surgical approaches [35,37].
Based on the results of the MAGIC study, perioperativeCT has been widely adopted and included in guidelines
[38] in Europe while CRT as performed in INT-0116
trial represents the therapy standard in most centers in
the US [39].
A detailed comparison of the INT-0116 study and the
MAGIC trial is provided in Table 1; this comparison
shows that OS in INT-0116 was about 42% after five
years in the CRT arm while 36.3% of patients were alive
after three years in the MAGIC study. The survival ad-
vantage of INT-0116 vs. MAGIC was coherent in terms
of DFS, and was despite the fact that: 1. patients had
more advanced carcinomas in INT-0116 trial (see
Table 1), and: 2. patients in the MAGIC trial received
D2 resection in >40% of cases vs. 10% in INT-0116. On
the other hand, by study design, patients included in
INT-0116 trial had already undergone curative resection
at randomization. Patients in the MAGIC trial were ran-
domized before any treatment. Cunningham et al.
reported that surgery “considered curative by the operat-
ing surgeon” was performed in 69.3% of patients in the
CT arm, and 66.4% in control arm [34]. To our best
knowledge, the exact rate of R0, R1 and R2 resections
has never been reported by the authors, nonetheless the
rate of 69.3% was recognized by some authors as R0 re-
section rate in the MAGIC trial [29,40,41]. According to
a statement taken from personal communication pub-
lished by Smalley et al. in their update on the INT-0116
trial, D. Cunningham stated that R1 resection was espe-
cially common in the GEJ carcinomas [29].
The differences in study design between both trials
must be emphasized as they hamper any reasonable
comparison and explain the worse OS in the control
arm of the MAGIC trial (as compared to INT-0116) des-
pite the higher rate of D2 resections performed in the
study population.
Therefore a direct comparison between MAGIC and
INT-0116 is not possible. This explains the many differ-
ent interpretations in the literature and the different
therapeutic approaches after publication of the MAGIC
trial in the US and in Europe.
Confirmation of survival advantages by adjuvant CT vs.
surgery alone in D2-dissected gastric cancer patients
While the superiority of CRT / CT vs. surgery alone in
Western trials might be due to inadequate surgery, this
is certainly not the case in studies on Eastern popula-
tions. As already mentioned, Kim et al. [28] confirmed
the survival advantage of adjuvant CRT in a non-
randomized population of D2-dissected patients.
In addition, the advantage of adjuvant therapeutic regi-
mens vs. surgery alone was confirmed by Eastern rando-
mized trials. First, Sakuramoto and coworkers reported
on S-1 (TS-1), an orally active combination of tegafur,
gimeracil, and oteracil. The authors reported in the
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cer (ACTS-GC) on 1059 randomly assigned patients
with gastric carcinoma who underwent D2 surgery with
or without adjuvant S-1 [42]. In accordance with the
other trials they found a significant increase in OS and
DFS [43] (see Table 1 for details). Nakajima et al.
reported on 190 early stage gastric carcinoma patients
(T2N1-2) randomized to adjuvant uracil-tegafur or sur-
gery alone [44]. All patients received extended lymph
node resection and both OS and DFS were significantly
better in the CT group (HR 0.46, 13% difference in sur-
vival at 4 years).
The latest Eastern results were provided by the capeci-
tabine and oxaliplatin adjuvant study in stomach cancer
(CLASSIC), 1035 patients in South Korea, China, and
Taiwan were randomized to adjuvant CT vs. surgery only
[45]. The difference in 3-year OS was minor compared
to other studies (83% vs. 78%, p=0.0493), nevertheless
there was a significant and considerable difference in
DFS; details are provided in Table 1.
Therapeutic approaches in GEJ carcinoma patients –
changes in treatment approaches during the last years
In the last years, therapeutic approaches on GEJ carcin-
oma patients were essentially based on results derived
from the INT-0116 [27] and the MAGIC [34] trial.
Standard of care in the US was mainly adjuvant CRT as
described in the intergroup protocol while European
oncologists and surgeons preferred the perioperative CT
as described in the MAGIC protocol [46]. However,
given the shortcomings of both, the low proportion of
GEJ carcinoma patients included, and the current dis-
cussion about a closer relation of GEJ to esophageal car-
cinoma [17], it is now time to reconsider therapeutic
strategies for GEJ tumors. This applies even more as evi-
dence shows that adjuvant therapeutic strategies (CT
and CRT) in esophageal carcinoma patients have led to
disappointing results [47-50].
In contrast to the results in gastric carcinoma, neoad-
juvant regimens seem to surpass adjuvant strategies in
esophageal carcinoma patients [51]. Recently, more evi-
dence for neoadjuvant treatments was provided by the
OEO2 trial [52] which showed a significant survival
benefit (5-year OS 23% vs. 17.1%; p=0.003) with neoad-
juvant CT and surgery vs. surgery alone, nevertheless a
similar trial in the US (RTOG trial 8911, US Intergroup-
113) could not demonstrate a survival advantage [53].
Notwithstanding these contradictory results in single
trials, meta-analyses [51,54,55] clearly indicate survival
benefits of neoadjuvant CRT and CT regimens as com-
pared to surgery alone in locally advanced esophageal
and GEJ carcinoma. When interpreting these findings, it
must be considered that the mentioned analyses include
a majority of esophageal SCC [47-51,54,55], thereforethere is still an ongoing discussion which results and
therapeutic approaches may be extrapolated on GEJ
adenocarcinoma [41]. A trial reported by Walsh et al. in
1996 strongly suggested a superiority of neoadjuvant
CRT and surgery vs. surgery alone in patients with (only)
adenocarcinoma of the GEJ, the esophagus or the cardia.
The authors randomized 113 patients with adenocarcin-
oma of the GEJ, the esophagus, or the cardia to neoadju-
vant CRT (40Gy + FU + Cisplatin) and surgery vs.
surgery alone [56]. Multimodal therapy resulted in sig-
nificantly improved OS vs. surgery alone (median sur-
vival in CRT and surgery arm was 16 months, as
compared with 11 months in the surgery only arm;
p=0.01).
In essence, therapeutic approaches in GEJ carcinoma
patients have recently been dominated by the protocols of
the two landmark trials (INT-0116 and MAGIC).
Although there was evidence in favor of neoadjuvant regi-
mens, similar to esophageal therapeutic strategies, patients
with GEJ adenocarcinoma were treated either periopera-
tively or with an adjuvant approach. The basic question if
radiation therapy in addition to surgery and chemotherapy
should be applied in GEJ- and in gastric cancer therapy
has therefore been raised again by recent results.
Latest results and new evidence suggesting a benefit of
radiation therapy in addition to neoadjuvant, adjuvant or
perioperative chemotherapy in GEJ patients
As mentioned above, meta-analyses showed neoadjuvant
therapy to improve OS compared with surgery alone for
esophageal cancer, including GEJ. A benefit for neoadju-
vant CRT vs. CT alone has been suggested but was not
clearly demonstrated [51].
In the discussion about CRT vs. CT as a neoadjuvant
therapy, evidence in favor of CRT has emerged during the
last years. A phase III trial conducted by Stahl et al. who
compared a total of 126 patients receiving either neoadju-
vant CT followed by surgery or neoadjuvant CRT followed
by surgery [57]. Although the study was closed early and
differences were not statistically significant, results showed
a statistical trend to a survival advantage for CRT as com-
pared to CT in GEJ adenocarcinoma (3-year OS 27.7% vs.
47.4%, for details see Table 2). Another recently published
study is the ACCORD07 phase III trial [58]; the authors
reported on a significantly improved survival by CT with-
out irradiation as compared to surgery alone, their regi-
men was associated with marked general toxicity (see
Table 3 for comparison) their survival rates also being
worse than reported by other recently reported CRT trials
in comparable populations (see Table 2). Strong evidence
in favor of neoadjuvant CRT was provided by van Hagen
and coworkers. The authors recently reported on 368
patients with esophagus and junctional carcinoma in the
CROSS trial [59]. Patients with T1N+ or T2-T3N0-1
Table 2 Patient characteristics and survival in GEJ carcinoma trials
Clinical Trial ACCORD07 CROSS Stahl 2009
Number of
patients
randomized
224 368 126
Histology Adenocarcinoma: 100% Adenocarcinoma:
75%; SCC: 23%;
other: 2%
Adenocarcinoma: 100%
Tumor location Distal esophagus: 11%;
GEJ: 64%; stomach: 25%
Esophagus+: 73%;
GEJ: 24%; Unspecified: 3%
100% GEJ Siewert I: 55%,
Siewert II/III: 45%
Treatment in CT/CRT arm Cisplatin and FU§ in
perioperative combination
with surgery
Neoadjuvant carboplatin
& paclitaxel with concurrent
41.8/1.8Gy, followed by surgery
Neoadjuvant PLF#, followed by
cisplatin & etoposide with
concurrent 30/2Gy,
followed by surgery
Treatment in control arm‡ Surgery only Surgery only PLF#, followed by surgery
TNM in CT/CRT arm* T0: 3%; T1-2: 39%;
T3-4: 58%; N0: 33%;
N+: 67%; M0: 99%; M1: 1%
T1-2: 16%; T3-4: 84%;
unspecified T: 1%;
N0: 33%; N+: 65%;
unspecified N: 2%
T1-2: 0%; T3: 92%; T4: 8%;
N0: 64%; N+: 36%
TNM in control arm‡ * T1-2: 32%; T3-4: 68%;
N0: 20%; N+ 80%;
M0: 93%; M1: 7%
T1-2: 20%; T3-4: 79%;
unspecified T: 2%;
N0: 31%; N+: 64%;
unspecified N: 5%
T1-2: 0%; T3: 92%; T4: 8%;
N0: 37%; N+: 63%
OS in CT/CRT arm 5-year: 38% (p=0.02)† 5-year: 47%; 3-year: 58%;
median: 49.4 months (p=0.003)†
Median: 33.1months;
3-year: 47.4% (p=0.07)†
OS in control arm‡ 5-year: 24% (p=0.02)† 5-year: 34%; 3-year: 44%;
median: 24 months (p=0.003)†
Median: 21.1months
3-year: 27.7% (p=0.07)†
DFS in CT/CRT arm 5-year: 34% (p=0.003)† Median DFS not
reached (p<0.001)†
3-Y: 41.3% (P not significant,
value not reported)†
DFS in control arm‡ 5-year: 19% (p=0.003)† Median DFS 24.2
months (p<0.001)†
3-Y: 24.9% (P not significant,
value not reported)†
Postoperative
mortality in
CT/CRT arm
4.6% (p=0.76)† 4% (P not significant,
value not reported)†
10.2% (p=0.26)†
Postoperative
mortality in
control arm‡
4.5% (p=0.76)† 4% (P not significant,
value not reported)†
3.8% (p=0.26)†
R0 resection
rate in CT/CRT arm
84% (p=0.04)† R0: 92% (p<0.001)† 72% (P not significant,
value not reported)†
R0 resection
rate in control arm
74% (p=0.04)† R0: 69% (p<0.001)† 69% (P not significant,
value not reported)†
Complete response
in CT/CRT arm
Unspecified 29% (23% in adenocarcinoma
patients, 49% in SCC patients)
15.6% (p=0.03)†
Complete response
in control arm‡
- - 2% (p=0.03)†
Tumor free LN
at time of surgery
in CT/CRT arm
33% (p=0.054)† 69% (p<0.001)† 64% (p=0.01)†
Tumor free LN
at time of surgery
in control arm‡
20% (p=0.054)† 25% (p<0.001)† 37% (p=0.01)†
+ Locations of esophageal carcinomas were further specified as follows: proximal third: 2%; middle third: 13%; distal third 58%.
‡ Control arm in ACCORD07 and CROSS was surgery only; Stahl 2009 had no surgery only arm, we considered CT without radiotherapy as control arm in this
table.
§ FU: fluorouracil.
# PLF: cisplatin, fluorouracil, and leucovorin.
* TNM in ACCORD07 is pathologically (pTNM) staged; TNM in CROSS is clinically (cTNM) by means of endoscopic ultrasonography, computed tomography (CT), or
18F-fluorooxyglucose positron-emission tomography; TNM in Stahl 2009 is clinically for T-staging (uT), but pathological for N-staging.
† All mentioned p-values refer to comparison of the specified factor between CT/CRT arm, and control arm.
Patient characteristics and outcome of patients with GEJ- and esophageal carcinoma; in ACCORD07 and CROSS trial, surgery only arm was regarded as control
arm; in Stahl 2009, neoadjuvant PLF without irradiation followed by surgery was considered control arm while neoadjuvant CRT was considered CT/CRT arm.
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Table 3 Comparison of toxicity and side effects in different GEJ carcinoma trials
Clinical Trial ACCORD07 CROSS Stahl 2009
Number of patients
randomized
224 368 126
Patients with at
least grade 3 toxicity
38% Hematologic: 7.6%
All other: 13%
Unspecified
Grade 3 – and
4 toxicity in control arm
- - 5% (CT arm as control arm)
Grade 3–4 leukopenia
during CT/CRT
5.5% 6% 12%
Grade 3–4 neutropenia
during CT/CRT
20.2% 2% unspecified
Grade 3–4 thrombocytopenia
during CT/CRT
5.5% 1% 5%
Progressive disease during
preoperative therapy
11% Absolute number unspecified;
7 patients (4%) did not undergo
surgery because of disease progression
10%
Deaths during CT/CRT 1% 1% One patient (2%) died in CT group;
none died in CRT group
Side effects and toxicity in GEJ carcinoma trials; in CROSS- and ACCORD07 trial, surgery only was defined as control arm; in Stahl 2009, CT arm was considered as
control arm, CRT was considered as CT/CRT arm.
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http://www.ro-journal.com/content/7/1/192tumors were included, the majority presenting with
adenocarcinoma of the distal or junctional esophagus.
Patients were randomly assigned to CRT followed by sur-
gery, and to surgery alone. CRT consisted of carboplatin
and paclitaxel as well as a total radiation dose of 41.4Gy
given in 23 fractions of 1.8Gy each. The planning target
volume (PTV) included the primary tumor with radial
margins of 1.5 cm and proximal and distal margins of 4
cm. In addition, any enlarged lymph nodes were included.
If the tumor extended into the stomach, a distal margin of
3 cm was chosen; further details are summarized in
Table 2. Patients underwent surgery after CRT as soon as
possible (median time: 6.6 weeks), and patients in the sur-
gery group were treated as soon as possible after
randomization. Interestingly, the authors found no signifi-
cant difference in surgical complications or postoperative
mortality between CRT and surgery only groups. Surgeons
achieved significantly more R0 resections in the CRT
group as compared to the surgery only group (92% vs.
69%; p<0.001). After completion of a median follow-up
time of 45.4 months for surviving patients, an intention to
treat analysis showed a median OS of 49.4 months in the
CRT arm vs. 24.0 months in the surgery only group (for
details see Table 2). These results are markedly better than
those achieved by other therapeutic approaches. The
authors reported that the survival difference was signifi-
cant for all histological subgroups and the benefit of CRT
was consistent across subgroups without any significant
interaction identified. Toxicity of CRT was very low in
terms of hematologic and non-hematologic side effects
(see Table 3 for details).
In summary, recent data in GEJ carcinoma indicate a
survival benefit of neoadjuvant CRT and CT in cura-
tively resectable patients. Due to a trend for bettersurvival of CRT vs. CT as reported by Stahl and cowor-
kers and because of the substantially longer survival
reported in the CROSS trial, CRT as performed in the
CROSS trial should be considered as a standard treat-
ment of patients with potentially curatively resectable
GEJ carcinoma in tumor stages >T1N0.
Latest data on therapeutic approaches in gastric
carcinoma – new evidence for adjuvant CRT vs.
perioperative CT
Recent trials in Eastern populations include the already
mentioned CLASSIC trial which demonstrated in a large
population in South Korea, China, and Taiwan, that
capecitabine and oxaliplatin in an adjuvant setting after
D2 gastrectomy is significantly associated with longer
DFS when compared to surgery alone (see Table 1). In
another Eastern population, Lee et al. conducted the
ARTIST trial to compare CT vs. CRT; the concept being
similar to the above mentioned Stahl trial, which was
conducted in GEJ, to demonstrate superiority of CRT
and surgery vs. CT and surgery in gastric carcinoma
[60]. Although DFS was not significantly increased by
CRT vs. CT, the authors observed a statistical trend to
better DFS with CRT (78.2% vs. 74.2% after 3 years). In
a subgroup analysis of patients with positive pathologic
nodes, the advantage on DFS for CRT vs. CT was signifi-
cant; after three years, a difference of 5% more disease-
free patients was achieved by adjuvant CRT as compared
to CT (p=0.0471; details are summarized in Table 1).
Although subgroup analyses should be interpreted with
caution, the high number of patients provides in our opin-
ion sufficient power in favor of adjuvant CRT in patients
with positive lymph nodes. For the whole population in
the ARTIST trial, it must be taken into account that
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cates that better local tumor control by CRT as compared
to CT outweighs toxic effects only after a sufficient obser-
vation time. After three years there are still a considerable
number of patients at risk for relapse; so effects on tumor
control might lack significance in this early analysis as
compared to long-term observations. The secondary end-
point (OS) was not (yet) analyzed by the authors due to a
low number of events [60]. The acute toxicity profile of
both arms was comparable with only slightly more grade 3
neutropenia in the CRT arm and a higher rate of patients
with grade 2–3 hand-foot syndrome in the CT group
(13.7% vs. 10.6%; see Table 1 for further details). On the
basis of these data, the ARTIST-2 trial was proposed that
should compare CT vs. CRT in patients with node-
positive gastric cancer [60].
Interestingly, Zhu et al. recently reported on a similar
trial conducted in a Chinese population. As further
detailed in Table 1, the authors compared adjuvant CT
alone to adjuvant CRT with intensity-modulated radio-
therapy (IMRT) in a randomized setting consisting of
380 curatively D2-resected patients [61]. When com-
pared to Lee et al. (ARTIST; [60]), Zhu and coworkers
observed a significant difference in DFS between the
therapeutic regimens not only in patients with positive
nodes but in the whole population after an observation
time of at least five years or until death of the patient.
Although a direct comparison between the populations
in terms of TNM-stage is hampered by different staging
patterns (AJCC 6th vs. 7th version), it is most likely that
the stronger effect on DFS as compared to the ARTIST
trial is due to the: 1. more advanced patients, especially
in terms of lymph node involvement; this is also sug-
gested by the increased rate of patients in the Chinese
trial as compared to the ARTIST study, who died mainly
because of local recurrence (Zhu et al.: 19.7% vs. ART-
IST: 6.6%) or: 2. the longer observation time, as
described above, the observation time in the Korean trial
might be relatively short, considering the high number
of patients still at risk for relapse.
Both the data provided by the ARTIST trial and by the
Chinese study lead to the assumption that gastric carcin-
oma patients benefit the more from CRT as compared to
CT, the more advanced their carcinomas are. This as-
sumption is further supported by a small trial reported
by Yu et al., the authors described in 68 randomly
assigned advanced gastric carcinoma patients (T3-4 and/
or N+) a significant superiority of adjuvant CRT with
45Gy irradiation applied by IMRT and FU/FA as com-
pared to adjuvant FU/FA only (3-yr OS: 67.7% vs. 44.1%;
p=0.037) [62]. Although the collective in this study was
supposedly underpowered, results add to the hypothesis
that more advanced gastric carcinoma patients benefit
from CRT as compared to CT. Additionally the Chinesetrials emphasize the need for further implementation of
IMRT in radiotherapy of gastric carcinomas.
If these encouraging results can be reproduced in
Western populations is undetermined. As mentioned
above, there are considerable inconsistencies in terms of
clinical results between trials conducted on Western
patients and trials on Eastern patients. It is not clear if
these differences were caused by differences in tumor
biology or by other epidemiological factors.
In Western patients, there are currently no large ran-
domized post-MAGIC results on CRT vs. CT in gastric
carcinoma patients; retrospective data provided by Dik-
ken et al. [63] on a European population of 91 gastric
cancer patients undergoing CRT even suggested D2-
dissected patients in this population (n=25) did not
benefit from adjuvant CRT in terms of survival as com-
pared to surgery only. Given this inconsistency with earl-
ier results and the underpowered population size, the
authors proposed a large randomized trial to compare
CRT vs. perioperative CT in Western patients with gas-
tric cancer. This currently ongoing study is the CRITICS
trial (NCT00407186; [40]) which compares perioperative
CT (epirubicin, cisplatin, capecitabine; ECC) and sur-
gery, with neoadjuvant CT, followed by surgery and
adjuvant CRT (45Gy in 25 fractions; concurrent capeci-
tabine and cisplatin).
Taken together, superiority of CRT vs. CT in gastric
carcinoma patients is suggested by Eastern trials, espe-
cially for advanced but curatively resectable patients.
Nevertheless, the situation is not as clear as in GEJ car-
cinomas, because perioperative CT as performed in the
MAGIC trial has until now not been compared to CRT
in a randomized setup. The most important ongoing
trial to address this topic is the CRITICS trial, which is
estimated to complete accrual in December 2013.
Given the results of the Korean and the Chinese trials,
and the difficult comparison of the INT-0116 and the
MAGIC trial, CRT seems to be at least equal to CT in
gastric cancer (excluding GEJ carcinoma). In Eastern
populations, recent results strongly indicate a longer
DFS by CRT as compared to CT in advanced patients
(especially N+); if these data can be reproduced in West-
ern patients will be clarified by the CRITICS trial. An-
other reason for the good results of the Chinese trial
might be the utilization of IMRT which successively
replaces 3D conformal radiotherapy (3DCRT) in gastric
and GEJ carcinoma treatment.
Radiotherapy in GEJ and gastric carcinoma – practical
considerations, latest technical advances and reduction of
side effects by IMRT
As mentioned above, local recurrence contributes to a
worse prognosis in gastric and GEJ carcinoma. External
beam radiotherapy (EBRT) in an adjuvant setting for
Figure 1 (See legend on next page.)
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Figure 1 VMAT treatment plans for gastric and GEJ carcinomas. (a-c): Volumetric intensity-modulated arc therapy (VMAT) plan (MonacoW,
Elekta, Crawley, UK) of a patient with a junctional carcinoma in the adjuvant situation. Transversal (a), coronal (b), and sagittal (c) dose
distributions. Color wash and isodose lines are indexed in the insert. A total dose of 45Gy was applied. Note the expansion of the planning target
volume (PTV) to the distal esophagus and sparing of the posterior wall of the heart, both lungs, and the dorsolateral renal cortex in the left
kidney. (d): Cone beam computed tomography (CBCT) based position correction directly before the first therapy fraction after positioning based
on skin marks. Magenta: planning computed tomography (PCT); green: CBCT; both PCT and CBCT in mid-ventilation position. Manual position
correction was based on internal surrogate structures such as calcifications in the aorta. (e-g): VMAT plan of a patient with stomach (corpus)
carcinoma in the adjuvant situation. Transversal (e), coronal (f) and sagittal (g) dose distributions. Color wash and isodose lines are indexed in the
insert. A total dose of 45Gy was applied. Note the sparing of the dorsolateral renal cortex in the left kidney and the complete right kidney. (h):
CBCT based position correction directly before the first therapy fraction. Magenta: PCT; green: CBCT.
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geal and GEJ adenocarcinoma offers the possibility to
prevent local relapse if sufficiently large PTVs covering
tumor bed, gastric stump, anastomosis and D2-3 lymph
node regions [64] are treated [65]. For proximal tumors,
the distal part of the esophagus should be included; for
corpus/distal tumors [66] diaphragm/proximal duode-
num should also be covered.
Fulfillment of these criteria results in a geometrical
complex and large upper abdominal PTV in direct
vicinity of the liver, both kidneys and spinal cord which
may lead to therapy interruption and possible late tox-
icity. While total dose applied (45–50.4Gy) is below
spinal cord tolerance, irradiation of the kidney with ab-
lative doses can cause late renal toxicity which isFigure 2 23Na-images of patients treated with 3DCRT or IMRT. Axial o
corresponding morphological fat-saturated T2-weighted images (A.2 and B
d = dorsal and the cerebrospinal fluid (CSF) is marked with an asterisk *. Th
patient in B.1/B.2 respectively with 3DCRT, both after gastric cancer. Thoug
functional 23Na-images clearly depict a reduced 23Na-content (arrows) in thbecoming more and more relevant for long-term survi-
vors [67-69].
With conventional 2D techniques and 3DCRT, defin-
ition of the PTV was a compromise between kidney
sparing and PTV coverage. PTV size was reduced at the
cost of the risk of local relapse, but nevertheless at least
the proximal part of most frequently the left kidney had
to be irradiated with ablative doses [70,71].
The introduction of IMRT allows steep and concave
dose gradients and a highly conformal dose distribu-
tion also for large PTVs with complex geometry [72].
The combination of IMRT with image-guided radio-
therapy (IGRT) allows the daily precise application of
these highly conformal doses. Dosimetric analyses
have shown that IMRT can reduce the median kidneyrientated, color-encoded 23Na-images (A.1 and B.1) with the
.2) of the left kidney. Orientation is given in the images as v = ventral;
e patient shown in A.1/A.2 was treated with IMRT and the other
h both morphological images present unremarkable renal parenchyma,
e ventral area included in the field of high-dose radiotherapy.
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larger PTVs which cover all recommended regions at
risk for local relapse [73-75]. IMRT dose distribution
within the kidneys is also more favorable if compared
to conventional techniques: the functionally most im-
portant renal cortex is spared [65,74] (see Figure 1e-h).
Additionally even these lower doses are delivered at
lower single fractions, which can also have an impact
on sparing functional capacity [76]. However this ef-
fect has to be investigated by functional imaging and
laboratory values in long-term survivor populations.
First results with functional MRI have shown intact
kidney morphology, diffusion capacity and sodium
concentration in long-term survivors of gastric can-
cer treated by IMRT combined with modern chemo-
therapy doublets [77]. These results were consistent
with the observation that patients retained normal
creatinine (and creatinine clearance) levels and did
not show any clinical signs of late renal toxicity (see
Figure 2 [77]).
In GEJ and esophageal carcinoma treatment, Kole and
coworkers reported IMRT to reduce heart- and coronary
artery doses as compared to 3DCRT [78]. However, no
long-term clinical data are available about outcome in
terms of cardiac toxicity of both modalities. In the
neoadjuvant setting, IMRT with concurrent CT has also
been shown to be well tolerated, accomplished excellent
target coverage and normal structure sparing, and led to
appropriate response rates [79].
In the last years, modern IMRT techniques such as ro-
tational IMRT (VMAT/IMAT, RapidArc) and helical
tomotherapy have been introduced [80,81]. Volumetric
intensity-modulated arc therapy (VMAT) has the cap-
ability to further decrease treatment times (and with
that, the impact of intrafractional patient and organ mo-
tion on the effectively absorbed dose compared to IMRT
while still providing similar PTV coverage and organ at
risk sparing. Dosimetric comparisons indicated VMAT
to be a favorable treatment option for esophageal and
junctional carcinoma [82-86].
Further technical developments such as integrating
breath hold in the image-guided workflow can probably
further improve dose distribution parameters [87]. Steep
dose gradients can be precisely applied by all of these
techniques if combined with daily 3D soft-tissue based
image-guidance (see Figure 1a-d for GEJ carcinoma and
Figure 1e-h for gastric carcinoma; [88,89]). For gastric
cancer, kV or MV cone beam computed tomography
(CBCT) or ultrasound based techniques can be both
applied [90-93].
Data on radiation therapy of gastric- and GEJ carcin-
oma with protons are relatively rare. However, as
demonstrated by Welsh et al., intensity-modulated pro-
ton therapy may be able to further at least theoretically,reduce normal tissue exposure if compared to IMRT in
definitive therapy for locally advanced distal esophageal
tumors [94].
Clinical results of IMRT compared to 3DCRT regard-
ing outcome and acute and late toxicity profile have
been evaluated by some retrospective studies [95,96];
however no large randomized studies exist for gastric
cancer. In our own retrospective analysis, adjuvant CRT
with IMRT and modern chemotherapy doublets led to
better survival of patients with advanced gastric cancer
compared to the adjuvant combination of 3DCRT and
conventional chemotherapy [95,97], also in the long-
term follow-up [98].
A similar comparison of survival and local control
after IMRT vs. 3DCRT for esophageal cancer has been
completed by Lin et al. on a large retrospective cohort
[99]. In this study, OS, local control, and non-cancer-
related death were significantly better with IMRT when
compared to 3DCRT [99].
These first results are encouraging, however, large pro-
spective trials and long-term clinical and functional
investigations regarding risk organ functions are neces-
sary to evaluate the role of modern radiotherapy techni-
ques for gastric and GEJ carcinoma.
Conclusion
Recent data in GEJ carcinoma indicate a survival benefit
of neoadjuvant CRT in curatively resectable patients. Al-
though there are also data showing an effect of CT in
perioperative settings, both the trials by Stahl et al. and
the CROSS trial indicate a superiority of neoadjuvant
CRT as compared to perioperative CT. Surgery alone
without neoadjuvant or perioperative therapy should be
regarded suboptimal in these patients. In gastric carcin-
oma patients, on the other hand, the situation is differ-
ent as perioperative CT has not been compared to
adjuvant CRT in a randomized setting. In Asia, as sug-
gested by the results of the recently published ARTIST
trial and the Chinese data by Zhu and coworkers, CRT
is significantly superior in terms of DFS as compared to
adjuvant CT in advanced gastric carcinoma patients (es-
pecially N+ patients). Reliable conclusions about which
therapy should be preferred in Western patients will be
provided by the ongoing CRITICS trial. If radiotherapy
is performed, modern approaches such as IMRT and
image guidance should be applied, as these methods re-
duce dose to organs at risk and provide a more
homogenous coverage of PTVs.
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